Fate Therapeutics, Inc. (FATE)
2.11
+0.02
(+0.96%)
USD |
NASDAQ |
Oct 23, 16:00
2.11
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Gross Profit Margin (Quarterly) : -33.53% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -33.53% |
| March 31, 2026 | -124.6% |
| December 31, 2025 | -123.7% |
| September 30, 2025 | -85.35% |
| June 30, 2025 | -71.89% |
| March 31, 2025 | -104.6% |
| December 31, 2024 | -158.8% |
| September 30, 2024 | -49.87% |
| June 30, 2024 | 30.29% |
| March 31, 2024 | -150.4% |
| December 31, 2023 | -191.5% |
| September 30, 2023 | -143.8% |
| June 30, 2023 | -378.7% |
| March 31, 2023 | 92.89% |
| December 31, 2022 | 89.08% |
| September 30, 2022 | 78.69% |
| June 30, 2022 | 84.03% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | 87.07% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.82% |
| Return on Assets | -39.89% |
| Return on Invested Capital | -44.16% |
| Profit Margin (Quarterly) | -1.45K% |
| Operating Margin (Quarterly) | -1.50K% |
| Return on Net Operating Assets | -126.7% |